9 children with X-linked severe combined immunodeficiency have received a new form of gene therapy. Alain Fischer, Marina Cavazzana-Calvo and Salima Hacein-Bey-Abina, together with their teams at Inserm Unit 1163 and AP-HP, have just published these results in the New England Journal of Medicine.
In 1999, these researchers pioneered the treatment by gene therapy of children with a disease that left them without any immune defences. However, some of these children developed leukaemia after therapy. Following the development of safer therapeutic vectors, it was possible to start a new clinical trial in 2010.
4 years later, the results obtained and described in this scientific article are encouraging. 7 children treated using this method are now in good health.
For more information, see the press release “Les “bébés-bulle” ont 11 ans: L’efficacité de la thérapie génique est démontrée (“Bubble babies” are 11 years old: the efficacy of gene therapy is demonstrated),” published in July 2010
(Français) La composition du microbiote intestinal prédit l’efficacité et la tolérance de l’immunothérapie du cancer chez l’homme
Sickle cell disease : remission of disease symptoms in the world’s first patient treated using gene therapy
(Français) Exposition in utero aux perturbateurs endocriniens : les leçons du distilbène
Brand new intervertebral discs for back pain